Solve Therapeutics secures $120m for its ADC pipeline, reaching a total funding of $321m. Phase I studies for lead programs SLV-154 and SLV-324 to be completed with this new tranche. CloakLink technology used in both ADCs to enhance efficacy and stability. ADCs offer targeted cancer therapy with fewer side effects.

CEO Dave Johnson emphasizes Solve’s differentiated platform and mission for safer targeted therapies. Johnson’s success with VelosBio acquisition by MSD for $2.75bn adds credibility. The booming ADC sector attracts big pharma investments, with billion-dollar deals like Pfizer’s $43bn Seagen acquisition. Roche also active in ADC deals, with potential billion-dollar agreements.

MSD joins Solve’s backers as ADC sector continues to grow. MSD secures $700m for broad-cancer ADC asset in early November. Solve’s innovative approach attracts interest in the competitive cancer therapy market. ADCs offer a promising avenue for cancer treatment with more targeted and effective options.

Read more at Yahoo Finance: Solve Therapeutics raises $120m as MSD joins list of backers